Work

The Role of Next Generation Sequencing in the Molecular Diagnosis and Treatment of Retinoblastoma

Year: 2016
Type: dissertation
Study design: Observational Study
Abstract: Retinoblastoma, a rare cancer of the infant retina, is a major health problem in low-income countries. Genetic testing for retinoblastoma or identification of the underlying RB1 mutations is particularly essential to the clinical management of this disease. High-quality conventional genetic testing is unaffordable for the majority of afflicted families in underdeveloped areas. The dynamic field of next generation sequencing (NGS) has allowed for simultaneous variant detection in multiple samples at a higher throughput than traditional sequencing. We hypothesized that NGS technology is a prospective cost-effective supplement to the conventional genetic testing strategy for retinoblastoma. We compared the cost and sensitivity of the Pacific Biosciences and Illumina MiSeq sequencing platforms for RB1 mutation identification and report a 70% to 90% sensitivity of mutation detection. We further performed a cost-effectiveness analysis of an NGS-based testing strategy versus the conventional Visible Genetics Incorporated (VGI)-based testing strategy in the genetic testing of an individual affected with unilateral retinoblastoma and seven at-risk relatives. A comparison of costs and effectiveness, measured as the sensitivity of RB1 mutation detection, as well as the number of invasive eye exams under anaesthesia (EUAs) required in the case of false negatives, across the two strategies revealed that the NGS-based strategy was associated with both a lower cost and decreased effectiveness of mutation detection. Consequently, we do not recommend NGS implementation in molecular diagnostics for retinoblastoma. Since retinoblastoma patients are at risk of ototoxicity due to carboplatin, tests for known single nucleotide polymorphisms (SNPs) that are associated with platinum-induced ototoxicity, coupled with NGS for RB1 mutations may be useful to guide therapy. We hypothesized that genetic and clinical predictors of carboplatin-induced ototoxicity would inform therapy to reduce this risk. None of the polymorphisms examined in the TPMT, COMT, and ABCC3 genes were associated with the development of hearing loss after carboplatin treatment in our cohort of 71 retinoblastoma patients. Younger age at treatment initiation was identified as a significant risk predictor of hearing loss. This work represents the first attempt to examine the cost-effectiveness of NGS in retinoblastoma genetic testing as well as investigate genetic determinants of carboplatin-related ototoxicity in this cancer.
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: green
OpenAlex ID: W7132929015
Cites: 120
Cited by:
Related to: 10